Guggenheim raised the firm’s price target on Metsera (MTSR) to $62 from $56 and keeps a Buy rating on the shares, telling investors that preliminary 5-week amylin data for the MET-233i monotherapy program exceeded the firm’s expectations. Following the report of the data, the firm is increasing its view of MET-233i odds of success to 65% from 50%, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- Metsera obesity monotherapy data ‘looks competitive,’ says BofA
- Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz
- Morning Movers: Warner Bros. Discovery climbs after plans to separate
- Metsera, Inc. Reports Positive Phase 1 Trial Results
- Metsera announces topline data from Phase 1 trial of MET-233i